Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amphastar Pharma (NQ: AMPH ) 47.95 +0.72 (+1.52%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Amphastar Pharma < Previous 1 2 3 4 5 Next > AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024 August 07, 2024 AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace Why the growth investor may take a look at NASDAQ:AMPH. June 05, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article. Via Chartmill Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade May 16, 2024 The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property Exploring NASDAQ:AMPH's growth characteristics. May 15, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations Via Chartmill AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024 May 08, 2024 AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace NASDAQ:AMPH, an undervalued stock with good fundamentals. March 12, 2024 AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying. Via Chartmill Delving into NASDAQ:AMPH's Growth Prospects. February 28, 2024 Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? Via Chartmill Earnings Outlook For Amphastar Pharma February 27, 2024 Via Benzinga Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca May 01, 2024 The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies April 10, 2024 Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections... Via Benzinga Is NASDAQ:AMPH a Fit for Growth Investing Strategies? February 14, 2024 Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? Via Chartmill CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ February 13, 2024 CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily Is NASDAQ:AMPH a Fit for Growth Investing Strategies? February 07, 2024 Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. Via Chartmill Unlocking the Growth Potential of NASDAQ:AMPH. January 23, 2024 Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. Via Chartmill NASDAQ:AMPH is not too expensive for the growth it is showing. January 17, 2024 Looking for growth without the hefty price tag? Consider NASDAQ:AMPH. Via Chartmill Why NASDAQ:AMPH is Poised for High Growth. January 16, 2024 Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. Via Chartmill 3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential February 05, 2024 As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to. Via InvestorPlace Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating January 23, 2024 Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued. January 23, 2024 For those who appreciate value investing, AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is a compelling option with its solid fundamentals. Via Chartmill What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition January 19, 2024 Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion... Via Benzinga Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' January 17, 2024 On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. Via Benzinga Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. January 02, 2024 Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? Via Chartmill Should you consider NASDAQ:AMPH for growth investing? December 26, 2023 Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? Via Chartmill Cassava Sciences Stock Continues Showing Rising Relative Strength January 16, 2024 Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. Via Investor's Business Daily Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study December 28, 2023 On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. Via Investor's Business Daily Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher December 26, 2023 On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. Via Investor's Business Daily 3 Reasons Why Amphastar Is a Great Growth Stock December 26, 2023 Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great... Via Talk Markets 3 Stocks at the Forefront of Medical Innovation December 25, 2023 Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. Via InvestorPlace < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.